Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | DHODH | Q02127 | 13/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TACR3 | P29371 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4875991 | 0.87 | KDM4E (0.55) | PDE10ATSHRDHODHKMT2ATACR3 | |
| SCHEMBL1581468 | 0.84 | PDE10A (1.00) | PDE10ATSHRDHODHKMT2ALMNA | |
| Hydrochloric Acid SCHEMBL27511204 | 0.83 | PDE10A (0.97) | PDE10ATSHRDHODHKMT2ALMNA | |
| SCHEMBL5420345 | 0.82 | LMNA (0.49) | PDE10ATSHRDHODHKMT2ALMNA | |
| SCHEMBL4874592 | 0.77 | PDE10A (0.65) | PDE10ATSHRDHODHKMT2ATACR3 | |
| SCHEMBL4875465 | 0.75 | PDE10A (0.74) | PDE10ATSHRDHODHKMT2ATACR3 | |
| SCHEMBL9788773 | 0.75 | DHODH (0.80) | PDE10ATSHRDHODHKMT2ALMNA | |
| SCHEMBL2373562 | 0.75 | PDE10A (0.74) | PDE10ATSHRDHODHKMT2ALMNA | |
| SCHEMBL14106730 | 0.75 | PDE10A (0.72) | PDE10ATSHRDHODHKMT2ALMNA | |
| SCHEMBL4875432 | 0.74 | KDM4E (0.49) | PDE10ATSHRKMT2ALMNATACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261945-A1 | Compounds Having Activity at Nk3 Receptor and Uses Thereof in Medicine | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261945-A1 | Compounds Having Activity at Nk3 Receptor and Uses Thereof in Medicine | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261945-A1 | Compounds Having Activity at Nk3 Receptor and Uses Thereof in Medicine | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1812398-A1 | COMPOUNDS HAVING ACTIVITY AT NK3 RECEPTOR AND USES THEREOF IN MEDICINE | SmithKline Beecham Corporation (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006050991-A1 | COMPOUNDS HAVING ACTIVITY AT NK3 RECEPTOR AND USES THEREOF IN MEDICINE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006050992-A1 | COMPOUNDS HAVING ACTIVITY AT NK3 RECEPTOR AND USES THEREOF IN MEDICINE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261945-A1 | Compounds Having Activity at Nk3 Receptor and Uses Thereof in Medicine | CNR1, ACKR3, HCAR3 | PDE10A 2915/4885TSHR 94/4885DHODH 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.